Research & Development

Innovation for your health and well-being !

AXIOS Senolytics develops and exploits an existing portfolio of senolytic drug candidates (trademarks, patents, industrial property rights)and valorises its research in the framework of partnership agreements with major pharmaceutical companies, both in the form of R&D contracts and licensing agreements per therapeutic application.

Further developments are underway.

If you have any questions,please contact us at contact@axios-senolytics.com or by phone at

+33 (0)9.81.75.70.07.

R&D

Innovation for your health and well-being !

AXIOS Senolytics develops and exploits an existing portfolio of senolytic drug candidates (trademarks, patents, industrial property rights)and valorises its research in the framework of partnership agreements with major pharmaceutical companies, both in the form of R&D contracts and licensing agreements per therapeutic application.

Further developments are underway.

If you have any questions,please contact us at contact@axios-senolytics.com or by phone at

+33 (0)9.81.75.70.07.

R&D

Ours patents

Patents US 11,053,249 B2 (Jul. 6, 2021; United States) and AU 2017383148 (Sept. 3, 2021; Australia) relate to proteasome/immunoproteasome inhibiting beta-lactam compounds in the form of vectorised prodrugs with selective targeting and specific in situ activation by the catalytic subunits of the said proteasomes, aiming to avoid any adverse effects – a disruptive innovation providing a major competitive advantage.

The so-called “ubiquitin-proteasome” pathway is the main route of protein degradation in cells. The enzyme complex called “proteasome”, responsible for the proteolytic degradation of “ubiquitin” tagged proteins (damaged or abnormal proteins, regulatory proteins, transcription factors, enzymes, …), plays a major role in a large number of essential functions such as the control of the cell cycle or the regulation of signalling pathways, and is involved in many pathological processes (cancer, inflammatory diseases, neurodegenerative processes, strokes, …).

Cancer cells are particularly vulnerable to a class of pharmacotherapeutic molecules called “proteasome inhibitors” and are much more sensitive to inhibition than non-malignant cells. Proteasome inhibition leads to tumour cell apoptosis and furthermore induces anti-proliferative, anti-angiogenic and anti-inflammatory effects. The involvement of the immunoproteasome in many inflammatory and immune processes (i.e. generation and presentation of antigenic peptides, immune and inflammatory responses, control of gene expression under stress, autoimmune mechanisms, etc.) also makes it a prime target.

Our patents

Patents US 11,053,249 B2 (Jul. 6, 2021; United States) and AU 2017383148 (Sept. 3, 2021; Australia)relate to proteasome/immunoproteasome inhibiting beta-lactam compounds in the form of vectorised prodrugs with selective targeting and specific in situ activation by the catalytic subunits of the said proteasomes, aiming to avoid any adverse effects – a disruptive innovation providing a major competitive advantage.

The so-called “ubiquitin-proteasome” pathway is the main route of protein degradation in cells. The enzyme complex called “proteasome”, responsible for the proteolytic degradation of “ubiquitin” tagged proteins (damaged or abnormal proteins, regulatory proteins, transcription factors, enzymes, …), plays a major role in a large number of essential functions such as the control of the cell cycle or the regulation of signalling pathways, and is involved in many pathological processes (cancer, inflammatory diseases, neurodegenerative processes, strokes, …).

Cancer cells are particularly vulnerable to a class of pharmacotherapeutic molecules called “proteasome inhibitors” and are much more sensitive to inhibition than non-malignant cells. Proteasome inhibition leads to tumour cell apoptosis and furthermore induces anti-proliferative, anti-angiogenic and anti-inflammatory effects. The involvement of the immunoproteasome in many inflammatory and immune processes (i.e. generation and presentation of antigenic peptides, immune and inflammatory responses, control of gene expression under stress, autoimmune mechanisms, etc.) also makes it a prime target.

Inhibition of the proteasome/immunoproteasome is a new pharmacological targetand is proving to be a major economic challenge for the pharmaceutical industry. However, the inhibitors currently on the market or in clinical trials do not allow selective therapeutic targeting.

The “prodrugs” of the invention implement a transport and in situ activation mechanism allowing the selective treatment of cancers, tumours of the nervous system, neurodegenerative and/or neuroinflammatory processes such as those involved in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease or amyotrophic lateral sclerosis, angiogenic disorders and certain infectious diseases. Proteasome inhibition can be reversible or irreversible. Different families of prodrugs can be sold by therapeutic application in different pharmaceutical formulations.

Directly marketable, the prodrugs of the invention represent a real therapeutic advance likely to lead to significant socio-economic spin-offs and a challenge for the players in the field, especially since, according to recent estimates, the market for proteasome inhibitors would exceed one billion euros.

Inhibition of the proteasome/immunoproteasome is a new pharmacological target and is proving to be a major economic challenge for the pharmaceutical industry. However, the inhibitors currently on the market or in clinical trials do not allow selective therapeutic targeting.

The “prodrugs” of the invention implement a transport and in situ activation mechanism allowing the selective treatment of cancers, tumours of the nervous system, neurodegenerative and/or neuroinflammatory processes such as those involved in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease or amyotrophic lateral sclerosis, angiogenic disorders and certain infectious diseases. Proteasome inhibition can be reversible or irreversible. Different families of prodrugs can be sold by therapeutic application in different pharmaceutical formulations.

Directly marketable, the prodrugs of the invention represent a real therapeutic advance likely to lead to significant socio-economic spin-offs and a challenge for the players in the field, especially since, according to recent estimates, the market for proteasome inhibitors would exceed one billion euros.

Patent :integration of active molecules in selenium microalgae

25 July 2014 – FRANCE

Patent :integration of active molecules in selenium microalgae

25 July 2014 – FRANCE

Ours patents

Patents US 11,053,249 B2 (Jul. 6, 2021; United States) and AU 2017383148 B2 (Sept. 3, 2021; Australia) relate to proteasome/immunoproteasome inhibiting beta-lactam compounds in the form of vectorised prodrugs with selective targeting and specificin situ activation by the catalytic subunits of the said proteasomes, aiming to avoid any adverse effects – a disruptive innovation providing a major competitive advantage.

The so-called “ubiquitin-proteasome” pathway is the main route of protein degradation in cells. The enzyme complex called “proteasome”, responsible for the proteolytic degradation of “ubiquitin” tagged proteins (damaged or abnormal proteins, regulatory proteins, transcription factors, enzymes, …), plays a major role in a large number of essential functions such as the control of the cell cycle or the regulation of signalling pathways, and is involved in many pathological processes (cancer, inflammatory diseases, neurodegenerative processes, strokes, …).

Cancer cells are particularly vulnerable to a class of pharmacotherapeutic molecules called “proteasome inhibitors” and are much more sensitive to inhibition than non-malignant cells. Proteasome inhibition leads to tumour cell apoptosis and furthermore induces anti-proliferative, anti-angiogenic and anti-inflammatory effects. The involvement of the immunoproteasome in many inflammatory and immune processes (i.e. generation and presentation of antigenic peptides, immune and inflammatory responses, control of gene expression under stress, autoimmune mechanisms, etc.) also makes it a prime target.

Inhibition of the proteasome/immunoproteasome is a new pharmacological target and is proving to be a major economic challenge for the pharmaceutical industry. However, the inhibitors currently on the market or in clinical trials do not allow selective therapeutic targeting.

The “prodrugs” of the invention implement a transport and in situactivation mechanism allowing the selective treatment of cancers, tumours of the nervous system, neurodegenerative and/or neuroinflammatory processes such as those involved in Alzheimer’s disease, Parkinson’sdisease, Huntington’s disease or amyotrophic lateral sclerosis, angiogenic disorders and certain infectious diseases. Proteasome inhibition can be reversible or irreversible. Different families of prodrugs can be sold by therapeutic application in different pharmaceutical formulations.

Directly marketable, the prodrugs of the invention represent a real therapeutic advance likely to lead to significant socio-economic spin-offs and a challenge for the players in the field, especially since, according to recent estimates, the market for proteasome inhibitors would exceed one billion euros.

Patent :integration of active molecules in selenium microalgae – 25 July 2014 – FRANCE